MedTrace Logo

A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

NCT01044342 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.

Conditions

  • Cognition

Interventions

DRUG

AZD1446

capsule; single oral dose

DRUG

AZD1446

capsule, single oral dose

DRUG

donepezil

capsule, single oral dose

DRUG

Placebo

capsule, single oral dose

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044342 on ClinicalTrials.gov